FORSCHUNGSPROJEKTE UND PREISE

     Forschungsprojekte:

• FWF - Projekt Nummer I 4220-B
• FWF P 30924 B 26
• FWF PROJEKT NR. P25899-B23
• FWF PROJEKT NR. L 676-B18 (GERMAN VERSION)
• FWF PROJEKT NR. L 676-B18 (ENGLISH VERSION)
• DIE WIRKSAMKEIT VON MUSIK ALS ENTSPANNUNGSINTERVENTION BEI SCHILDDRÜSENKARZINOMPATIENTEN UNTER RADIOJODTHERAPIE
• WITTGENSTEINPREIS
  
  

  Preise der Univ.-Klinik für Nuklearmedizin Innsbruck:

   

•  Am 22.01.2020 wurde der Univ.-Klinik für Nuklearmedizin bei der OGNMB Zell am See der “Ilse-Zoller-Förderungspreis für Naturwissenschaften in der Nuklearmedizin” für die folgende Publikation verliehen:
  Klingler M, Summer D, Rangger C, Haubner R, Foster J, Sosabowski J, Decristoforo C, Virgolini I, von Guggenberg E. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. J Nucl Med. 2019 Jul;60(7):1010-1016.
  

• Ärztekammer Preisverleihung (31.12.2019) von Dr. Arthur Wechselberger an Frau Dr. Lorenza Scarpa für die Publikation:
  The ⁶⁸Ga/¹⁷⁷Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, Decristoforo C, Uprimny C, Lukas P, Horninger W, Virgolini I. Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800.

• 3 Platz Rudolf-Höfer-Preis 2019, presented at the Billrothhaus, Vienna, 09.04.2019 for the two publications:
  1. Klingler M, Summer D, Rangger C, Haubner R, Forster J, Sosabowski J, Virgolini I, Decristoforo C, von Guggenberg E. DOTA-MGS5, a new cholecystokinin-2 receptor targeting peptide analog with optimized targeting profile for theranostic use. J Nucl Med. 2019 Jul;60(7):1010-1016.
  2. Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. Site-specific stabilization of minigastrin analogs against enzymatic Degradation for enhanced cholecystokinin-2 receptor targeting. Theranostics. 2018 Apr 16;8(11):2896-2908.
  
  
• EANM Best Paper Award 2018, presented at the 31^st Annual Congress of the European Association of Nuclear Medicine, October 13-17, 2018 for the publication: 68Ga-PSMA-11 PET/CT in Primary staging of prostate Cancer: PSA and Gleason Score predict the intensity of Tracer accumulation in the Primary tumour. Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, HORNINGER W, Virgolini IJ. Eur J Nucl Med Mol Imaging 2017;44(6):941-949.
  
  
• 1. Rudolf-Höfer-Preis 2018, presented on the Billrothhaus, Vienna, Austria for the publication: "Early PET Imaging with 68Ga-PSMA-11 increases the detection rate of local recurrence in prostate Cancer patients with biochemical recurrence". Urpimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, Nilica B, Maffey-Steffan J, di Santo G, BEKTIC J, HORNINGER W, Virgolini IJ. Eur J Nucl Med Mol Imaging 2017;44(10):1647-1655.
  
  
• Radioactive Isotopes in Molecular Imaging & Therapy, 33rd International Austrian Winter Symposium & 13th Alpe Adria Nuclear Medicine, Joint Meeting, January 24th-27th 2018
  1., 2. & 3. Platz des Allgemeinen Förderungspreises Nuklearmedizin (2017) OGNMB an die Univ.-Klinik für Nuklearmedizin Innsbruck: Publikationen:
  1.„68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour”. Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):941-949.
  2.“Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.” Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, Roig LG, Kendler D, von Guggenberg E, Bektic J, Horninger W, Virgolini IJ. Eur J Nucl Med Mol Imaging. 2017 May;44(5):765-775.
  3.„Early PET imaging with 68Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.” Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, Nilica B, Maffey-Steffan J, di Santo G, Bektic J, Horninger W, Virgolini IJ. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1647-1655.